| ［1］ 周艳萌.抗乙型肝炎病毒的中药研究进展.时珍国医国药,2005,3(10):21~24 Zhou Y M.Lishizhen Medicine and Materia Medica Research,2005,3(10):21~24 ［2］ 刘茂昌,王贵强,朴文花,等.HBV cccDNA在2.2.15 细胞表达的动态观察.中华实验和临床病毒学杂志,2005,19(4):391~394 Liu M C,Wang G Q,Piao W H,et al.Chinese J Exp Clin Virol,2005,19(4):391~394 ［3］ Sung J J, Wong M L, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology,2005,128: 1890~1897 ［4］ 庄立伟,陆海英,于岩岩,等. HBV cccDNA荧光定量检测方法的建立及应用. 中华实验和临床病毒学杂志,2007,21(2):182~184 Zhuang L W,Lu H Y,Yu Y Y,et al.Chinese EXP and Clin Virol,2007,21(2):182~184 ［5］ WerleLapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology, 2004,126（7）:1750-1758 ［6］ 周俊. 中药复方天然组合化学库与多靶点作用机理. 中国中西医结合杂志,1998,18(2):67 Zhou J.Chinese J Integrative Medicine,1998,18(2):67 ［7］ Tang H, Delgermaa L, Huang F, et al. The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J Virol, 2005,79(9):5548~5556 ［8］ Guan S H, Lu M J, Grunewald P, et al. Interferonresponse inchronic hepatitis B transfected hepG2.2.15 cells is partially restored by lamivudine treatment. World J Gastroenterol, 2007,13(2): 228~235 ［9］ Weber O, Schlemmer K H, Hartmann E, et al. Inhibition of human hepatitis B virus(HBV) by a novel nonnucleosidic compound in a transgenic mouse model，Antiviral Research. 2002,54：69~78 ［10］ Morrey J D, Bailey K W, Korba B E, et al. Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine. Antiviral Reseach,1999,42:97~108 ［11］ Deres K, Schroder C H, Paessens A, et al. Inhibition of hepatitis B virus replication by druginduced depletion of nucleocapsids. Science,2003,299:893~895 ［12］ Kakimi K, Guidotti L G, Kozuka Y, et al. Natural killer T cell activation inhitits hepatitis B virus replication in vivo. J Exp, 2000,192(7):912~930 ［13］ Mehta A S, Gu B H, Conyers B, et al. α-Galactosylceramide and novel synthetic glycolipids directly induce the innate host defense pathway and have direct activity against hepatitis B and C viruses. Antimicrobial agents and Chemotherapy,2004,48(6):2085~2090 ［14］ Guidotti L G, Matzke B, Schaller H, et al. Highlevel hepatitis B virus replication in transgenic mice. J Virol,1995,68(11):6158~6169 ［15］ 孔祥平, 吴庆洲, 罗显荣, 等. 复制型HBV转基因小鼠遗传稳定性研究. 中国生物工程杂志,2008,28(5):17~21 Kon X P, Wu Q Z, Luo X R, et al. China Biotechnology, 2008,28(5):17~21 ［16］ 贾伟, 赵立平, 陈竺. 系统生物医学：中西医学研究的汇聚. 世界科学技术—中医药现代化,2007,9(2):1~5 Jia W,Zhao L P,Chen Z.World Science and Technology Modernization of Traditional Chinese Medicine and Materia Medica,2007,9(2):1~5 |
